Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Current Assets (2016 - 2026)

Perspective Therapeutics' Current Assets history spans 16 years, with the latest figure at $275.4 million for Q1 2026.

  • On a quarterly basis, Current Assets rose 27.63% to $275.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $275.4 million, a 27.63% increase, with the full-year FY2025 number at $148.4 million, down 35.81% from a year prior.
  • Current Assets hit $275.4 million in Q1 2026 for Perspective Therapeutics, up from $148.4 million in the prior quarter.
  • Over the last five years, Current Assets for CATX hit a ceiling of $294.2 million in Q2 2024 and a floor of $16.8 million in Q4 2023.
  • Historically, Current Assets has averaged $137.7 million across 5 years, with a median of $148.4 million in 2025.
  • Biggest five-year swings in Current Assets: plummeted 68.36% in 2023 and later surged 1272.93% in 2024.
  • Tracing CATX's Current Assets over 5 years: stood at $53.2 million in 2022, then crashed by 68.36% to $16.8 million in 2023, then surged by 1272.93% to $231.2 million in 2024, then tumbled by 35.81% to $148.4 million in 2025, then surged by 85.56% to $275.4 million in 2026.
  • Business Quant data shows Current Assets for CATX at $275.4 million in Q1 2026, $148.4 million in Q4 2025, and $178.5 million in Q3 2025.